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The incidence of gastric cancer (GC) increases significantly after the fifth decade and palliative chemotherapy is the ultimate treatment
in the majority of patients. We investigated safety and efficacy of a weekly regimen with cisplatin, fluorouracil and leucovorin as first-
line chemotherapy for elderly patients with advanced GC. Chemotherapy-naive patients older than 65 years were considered eligible
for study entry. Frail elderly patients were identified and excluded according to the following criteria: age 485 years, dependence in
one or more activities of daily living (activities of daily living and instrumental activities of daily living scales), three or more comorbid
conditions, one or more geriatric syndromes. Chemotherapy consisted of 1-day per week administration of intravenous cisplatin
35mgm
 2, 6S-stereoisomer leucovorin 250mgm
 2 and fluorouracil 500mgm
 2 (PLF). Patients were re-evaluated after eight
weekly cycles and six additional weekly administrations were planned for patients without disease progression. A 5-day subcutaneous
filgrastim (5mgKg
 1day
 1, days þ1–þ5) was used after the first treatment delay for neutropenia and maintained thereafter. In the
whole group, the best intention-to-treat overall response rate was 43% (95% CI: 30–56%). The time to disease progression and the
median survival time were 5.3 and 8.6 months, respectively. Fatigue was the commonest nonhaematologic toxicity (71% of the
patients). Filgrastim was used in 30 patients who showed grade II (20 patients) or grade III (10 patients) neutropenia. Neither grade IV
toxicity nor toxic deaths were observed. The weekly PLF regimen resulted safe and effective in elderly patients with advanced GC.
This outpatient regimen is based on old and low-cost drugs and it may represent an alternative to new and more expensive
combinations.
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Gastric cancer is among the most common causes of cancer-related
death, and palliative chemotherapy is the ultimate treatment in the
majority of patients (Wils, 1998). In recent years, second-
generation combination chemotherapy regimens have produced
high response rates and impressive survival times (Cascinu et al,
1997; Webb et al, 1997; Hill and Cunningham, 1998). However, the
activity of these treatments has been demonstrated in patients with
good performance status and young age and, therefore, they do not
reflect the characteristics of patients in the community with
advanced gastric cancer (Tebbutt et al, 2002). Current epidemio-
logical data show that gastric cancer rarely occurs before the age of
40 years, its incidence increases thereafter and peaks in the seventh
decade (Greenlee et al, 2000).
Patients older than 65 years have been often excluded from or
underrepresented in the study populations of combination
chemotherapy trials (Hutchins et al, 1999). This demographic
selection occurred in the populations of gastric cancer patients
treated with intensive combination chemotherapy regimens like
the ECF (Tebbutt et al, 2002) or the weekly PELF. The weekly PELF
(cisplatin, fluorouracil, epi-doxorubicin, leucovorin) regimen plus
filgrastim support yielded a 62% response rate and a median
survival time of 11 months in a large phase II trial (Cascinu et al,
1997). This efficacy was confirmed in subsequent studies (Cascinu
et al, 1998, 2001), but demographic data suggest that only a
minority of patients treated with the weekly PELF regimen were
older than 65 years. In the PELF trials, severe haematology and
nonhaematologic toxicities were uncommon, but more than half of
the patients had mild-to-moderate side effects and even using
routine filgrastim support, up to one-third of patients showed
grade II or III neutropenia (Cascinu et al, 1997, 1998, 2001).
To date, the development of active and safe regimens for
treating elderly patients with advanced gastric cancer should be
considered a relevant issue in medical oncology. Age itself is
not a contraindication to anticancer medical therapies
(Goodwin et al, 1996; Balducci and Beghe, 2000; Balducci and
Yates, 2000) and specific tools are available to identify nonfrail
elderly patients who could benefit from chemotherapy
(Goodwin et al, 1996; Balducci and Yates, 2000). Received 29 January 2003; revised 9 June 2003; accepted 15 July 2003
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lOn these bases, we sought to investigate the weekly combination
of cisplatin, fluorouracil and 6S-stereoisomer leucovorin (PLF) as
first-line chemotherapy for elderly patients with advanced gastric
cancer. Drugs, doses and pace of chemotherapy administrations
were those of the weekly PELF regimen, but without epirubicin.
This choice was made under the hypothesis that the omission of
the anthracycline could have reduced the incidence of neutropenia
with improved tolerability of chemotherapy to elderly patients. In
a pilot clinical trial, the weekly PLF regimen showed a favourable
activity/toxicity ratio and chemotherapy did not require routine
filgrastim support (Graziano et al, 2002).
MATERIALS AND METHODS
Patients characteristics
Chemotherapy-naive patients with pathologically confirmed,
relapsed, locally advanced or metastatic gastric cancer were
considered eligible for study entry. The study was addressed to
patients older than 65 years; frail elderly patients were excluded
according to the following criteria: age 485 years, dependence in
one or more activities of daily living, presence of three or more
comorbid conditions and presence of one or more geriatric
syndromes (Balducci and Yates 2000). The Katz and Lawton scales
were used to assess activities of daily living (Scott et al, 1997); the
Katz activities of daily living (ADL) rates the ability to perform
routine activities as bathing, dressing, feeding oneself or getting
into or out of bed, chairs and vehicles. The Lawton instrumental
activities of daily living (IADL) rates more sophisticated functions
as the ability to use the telephone, to shop, to handle money, to
prepare food or to perform other household tasks. Classic geriatric
syndromes which had to be excluded before study inclusion were:
dementia, delirium, severe depression, frequent falls, neglect and/
or abuse, and spontaneous fractures (Balducci and Yates, 2000).
The procedures for performing the above-mentioned geriatric
assessments were reported in the study protocol. Each patient was
evaluated from the same oncologist at each participating institu-
tion.
Additional inclusion criteria were: presence of measurable
disease, Eastern Cooperative Oncology Group (ECOG) perfor-
mance status 0–1, granulocytes count 41500ml, platelet count
4100000ml, serum creatinine o1.5mgdl
 1 with creatinine
clearance X60mlmin
 1 as estimated by using the Cockcroft–
Gault formula (Cockcroft and Gault, 1976), bilirubin level
o1.5mgdl
 1 and liver enzymes o1.5 times the institutional
upper limit. The protocol was approved by each local institutional
review board and written informed consent was obtained from all
participants.
Study design
Chemotherapy consisted of a 1-day per week administration of
intravenous cisplatin 35mgm
 2 with standard hydration and
glutathione 1.5gm
 2, followed by fluorouracil 500mgm
 2 and 6S-
stereoisomer leucovorin 250mgm
 2 (PLF). All patients received
emesis prophylaxis with 5-HT3 inhibitors. Routine prophylactic
support with granulocyte colony-stimulating factors was not
allowed, but filgrastim was introduced after the first treatment
delay for grade II/III neutropenia and maintained thereafter.
Erythropoietin was allowed for the treatment of anaemia, when
haemoglobin declined to a level p10mgdl
 1. Full doses of the
anticancer drug were given if granulocyte count was 41500ml
 1
and platelet count was 4100000ml
 1. In the case of any grade II
or more toxicity except alopecia, chemotherapy was delayed a
week and then restarted after full recovery. Doses of anticancer
drugs were not reduced in the case of grade II–III neutropenia, but
these patients started 5-day therapy with filgrastim 5mgKg
 1day
 1
(days þ1–þ5) after the first treatment delay. Similarly, dose of
anticancer drugs were not reduced after an episode of grade II–III
anaemia and erythropoietin was allowed when haemoglobin levels
were p10mgdl
 1. Patients with persisting neutropenia or
anaemia and who needed a second treatment delay received a
25% dose reduction of all drugs. Also, this dose reduction was
planned in the case of grade III toxicity, except alopecia. Patients
with unsolved grade II or more toxicity after two consecutive
treatment delays, or experiencing grade IV toxicity except alopecia
went off study.
Response and toxicity assessment
Pretreatment evaluation consisted of baseline studies including:
medical history, physical examination, blood chemistries, urinoa-
nalysis and ECG. Also, chest X-rays, abdominal computed
tomography or magnetic resonance, bone scan and any other test
to identify the extent of disease was performed. All patients had
physical examination and blood chemistries before each weekly
administration of chemotherapy and toxicity was graded according
to the National Cancer Institute Common Toxicity Criteria (NCI-
CTC, 1998). Tumour measurements for response assessment were
performed after eight weekly cycles; patients with responsive or
stable disease received six additional weekly cycles and they
underwent a second measurement at the end of the treatment
program. Follow-up controls were performed every 2 months
thereafter. The World Health Organization criteria (WHO, 1979)
were used to evaluate responses.
Statistical plan
The primary end point of this study was to determine the response
rate and the toxicity of the weekly PLF regimen in elderly patients
with advanced gastric cancer. The secondary objective was to
measure the time to disease progression and the survival time.
The study was conducted using the two-stage Simon (1989)
design. The sample size was calculated to reject a 10% response
rate in favour of a target response rate of 30%, with significance
level of 0.05 and a power of 0.90. In the initial stage, a total of 18
evaluable patients were to be entered and evaluated for response. If
there were p2 responses, accrual was to be stopped. If 42
responses were observed in the initial stage, then 19 additional
patients were to be entered in the second stage to achieve a total of
35 evaluable patients (assuming that two patients might be
inevaluable). If 46 responses were observed in 35 patients, an
accrual of at least 55 assessable patients was planned to ensure a
25% maximum width of the confidence interval with an expected
30% response rate. The time to disease progression (TTP) was
measured from the date of registration to the date of documented
disease progression or death. The survival time was measured
from the time of registration to the date of death resulting from
any cause.
RESULTS
From January 1999 to December 2001, 58 patients entered on this
study. Four patients did not complete eight weekly cycles due to
early progression (two patients), refusal after grade III fatigue (one
patient) and persistent grade II nephrotoxicity (one patient). The
side effects reported by these four patients were included in the
overall analysis of toxicity and they were considered as progres-
sions in the intention-to-treat analysis of response. The baseline
clinico-pathologic characteristics of the 58 patients are reported in
Table 1.
At the end of the treatment program, the best intention-to-treat
overall response rate in the 58 patients was 43% (95% CIs: 30–
56%) with five complete responses, 20 partial responses, 15 stable
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ldiseases and 18 progressions. The five complete responders
showed complete disappearance of disease signs after eight weekly
administrations and they confirmed the result at the second re-
evaluation. The complete responses were obtained in liver
metastases (two patients), lymphnodal metastases (two patients),
liver plus lymphnodal metastases (one patient). In all, 18 patients
achieved partial response after eight weekly cycles and two
additional patients with initial stable disease showed partial
response after 14 cycles. Three patients with stable disease after
eight PLF cycles showed disease progression at the second re-
evaluation. In the whole group, the median time to disease
progression was 5.3 months and the median survival time was 8.6
months.
Toxicity was generally mild and the maximun grade of
haematologic and nonhaematologic toxicities per patient is
reported in Table 2. According to the treatment protocol, the 30
patients who experienced grade II/III neutropenia started filgras-
tim which was maintained until the end of the treatment program.
The 5-day therapy with filgrastim was started after the fourth PLF
administration in 15 patients, after the fifth in nine patients and
after the sixth in the remaining six patients.
Fatigue was the commonest treatment-related toxicity and it
resulted grade I in 18 patients, grade II in 22 patients and grade III
in one patient. Anaemia was recorded in 31 patients whose
haemoglobin concentrations declined to a level of 10–12gdl
 1 in
26 patients and to 8–9.9gdl
 1 in 15 patients. None of the patients
showed episodes of grade III anaemia and blood transfusions were
not necessary in the study population. Other side effects like
stomatitis, peripheral neurotoxicity, nephrotoxicity were uncom-
mon and generally mild. At least one treatment delay was carried
out in 45 patients and 22 patients had a 25% dose reduction of
anticancer drugs. Neither grade IV toxicity nor toxic death were
observed.
DISCUSSION
Gastric carcinoma often occurs in the 60th and 70th decades, but
large trials of palliative chemotherapy in elderly patients are
almost lacking. To the best of our knowledge, six phase II studies
have been published in international peer-reviewed journals
between 1990 and 2002 (Wilke et al, 1990; Cascinu et al, 1994;
Cascinu and Catalano, 1995; Di Bartolomeo et al, 1995; Hartung
et al, 2000; Ikeda et al, 2002). In five of these trials, chemotherapy
consisted of leucovorin-modulated 5-fluorouracil in combination
with cisplatin, epi-doxorubicin, etoposide or mitomycin-C. A
phase II study investigated the toxicity profile and the activity of
single-agent doxifluridine (Ikeda et al, 2002). In general, the
tumour control rate seemed promising and no toxic death was
observed across all studies. Unfortunately, these trials often
enrolled patients with concomitant illnesses or poor performance
status and consequently, the number of elderly patients did not
exceed 30 in each of them. More recently, Tebbutt et al (2002) have
reported the results of a phase III trial investigating protracted
venous infusion 5-fluorouracil in oesophago-gastric cancer pa-
tients. In this study, there was no age limitation for patient
eligibility and chemotherapy achieved good results of palliation in
a cohort of patients with a median age of 72 years.
In the present investigation, the weekly combination of cisplatin,
fluorouracil and folinic acid showed promising tumour control
rate and it was safely delivered to nonfrail elderly patients with
advanced gastric cancer. Patients were treated on outpatient basis
and they showed good compliance to treatment with only one early
refusal. A specific assessment of either quality of life or clinical
benefit was not planned in this study; however, a record of
abdominal pain was performed by means of the memorial pain
assessment card and sustained pain relief was observed in 20 out of
28 patients (71%) who were monitored before, during and after
PLF chemotherapy.
A major issue in the field of anticancer chemotherapy for elderly
patients is the identification of prognostic indicators, which can be
used to balance benefits and risks of medical therapies. Many
Table 1 Characteristics of the 58 patients enrolled in the study
Number of patients 58
Sex ratio
Male 31
Female 27
Median age (range) 76years (67–82)
ECOG performance status
03 1
I2 7
Prior gastrectomy
Curative 40
Palliative 12
Not performed 6
Sites of the disease
Liver plus lymphnodes 17
Abdominal relapse plus lympnhodes 13
Liver 11
Lymphnodes 10
Primary tumour plus liver 4
Primary tumour plus lympnhodes 2
Lung plus liver 1
CEA level
o10ngml
 1 20
410ngml
 1 38
Table 2 Treatment-related toxicity in the 58 enrolled patients
Number of patients (%)
Adverse event Grade 1 Grade 2 Grade 3 Grade 4 All grades
Neutropenia 10 (17) 20 (35) 10 (17) 0 40 (69)
Thrombocytopenia 8 (14) 2 (3) 0 0 10 (17)
Anaemia 26 (45) 15 (26) 0 0 41 (71)
Nausea 21 (36) 4 (7) 0 0 25 (43)
Vomiting 19 (33) 9 (15) 0 0 28 (48)
Diarrhoea 8 (14) 2 (3) 0 0 10 (17)
Fatigue 18 (31) 22 (38) 1 (2) 0 41 (71)
Anorexia 15 (26) 10 (17) 0 0 25 (43)
Neuropathy 9 (15) 1 (2) 0 0 10 (17)
Nephrotoxicity 4 (7) 1 (2) 0 0 5 (9)
Mucositis 5 (8) 6 (10) 0 0 11 (19)
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date, several prognostic and predictive tools can be used to identify
frail and non-frail elderly patients (Reuben, 1997). Also, pharma-
cokinetic studies have clarified major differences in the metabo-
lism of anticancer drugs in the elderly with specific cares to be
used when treating patients ageing more than 65 years (Balducci
and Beghe, 1999).
There are many different methods to assess the functional status
in elderly patients and the comprehensive geriatric assessment
(CGA) is considered as one of the most complete tool for this
purpose (Repetto et al, 2002). The CGA requires a professional
team approach and it may be time consuming and costly (Ingram
et al 2002). For these reasons, alternative scales and less-extensive
methods have been implemented in cancer chemotherapy trials
for the evaluation of elderly patients. In particular, the IADL
and the ADL scales are considered as the most sensitive
assessments of function in older individuals (Balducci and
Beghe, 2000), and in both elderly men and women, increasing
score on the ADL–IADL scales is predictive of mortality
(Scott et al, 1997). In the present investigation, the CGA was not
included in the study plan, however, specific criteria to exclude
frail elderly patients, together with the accurate monitoring
of sideeffects and general measures for minimising toxicity
allowed the safe and successful administration of combination
chemotherapy in a population of patients whose median age
was 76 years. Indeed, the eligibility criteria were quite stringent
and a proportion of elderly patients could not be enrolled in
this trial. On the other hand, we opted for a conservative approach
since an unfavourable cost/efficacy ratio may occur when palliative
chemotherapy is administered to patients with advanced
gastric cancer and low-performance status or comorbities
(Janunger et al, 2001).
The favourable results of the weekly PLF regimen together with
its easiness of administration on outpatient basis and the use of
old, low-cost drugs make this treatment worth of further
investigation. At some point during chemotherapy, about half of
the patients received filgrastim and about 20% of them started
erythropoietin. These supports increased treatment-related ex-
penses and, therefore, they may have partially reduced the
advantage of low-cost chemotherapeutic agents. In this perspec-
tive, further assessments of the weekly PLF regimen could consider
a short 3-day filgrastim course between cycles and/or additional
treatment delays for neutropenia instead of the immediate use of
filgrastim after the first delay. PLF chemotherapy may represent a
valid alternative to more expensive combinations including CPT-
11 or oxaliplatin and it could be compared to palliative single-
agent fluorouracil in a randomised trial for elderly patients with
advanced gastric cancer.
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